ArticleAnnals of gastroenterological surgery2026
MicroRNA-941 Acts as a Novel Prognostic Predictor and Oncogenic Driver in Colorectal Cancer.
Article in Annals of gastroenterological surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aims to ascertain the expression status, clinical significance, and biological function of microRNA-941 (miR-941) in colorectal cancer (CRC). It elucidates the role of miR-941 in tumor development and the underlying mechanism involving the transcriptional repressor GATA binding 1 (TRPS1). Methods: Serum samples were collected from 150 CRC patients and 150 healthy controls to examine the relative amounts of miR-941. The diagnostic value of miR-941 was evaluated by plotting receiver operating characteristic (ROC) curves. Kaplan-Meier and Cox regression analyses were employed to assess the prognostic implications of miR-941. Functional experiments were conducted in CRC cell lines. The target gene of miR-941 was identified and confirmed through bioinformatics analysis and a dual-luciferase reporter assay. Results: An increased level of miR-941 was found in CRC patients and cell lines ( Conclusion: Our results identify miR-941 as a novel oncogenic driver in CRC through targeting of TRPS1, serving as a valuable prognostic indicator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.